Is IKT or INCR more profitable?

InterCure's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% InterCure N/A N/A N/A

Do analysts prefer LENZ or INCR?

LENZ Therapeutics currently has a consensus target price of $29.80, indicating a potential upside of 352.89%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe LENZ Therapeutics is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LENZ Therapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate INCR or CNTX?

Context Therapeutics has a consensus price target of $6.60, indicating a potential upside of 355.17%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Context Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Is INCR or CNTX more profitable?

InterCure's return on equity of 0.00% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Context Therapeutics N/A -59.95% -54.78%

Do analysts rate INCR or NERV?

Minerva Neurosciences has a consensus target price of $10.50, indicating a potential upside of 124.84%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Minerva Neurosciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is INCR or NERV more profitable?

Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Minerva Neurosciences N/A N/A -32.63%

Do analysts prefer INCR or SGMT?

Sagimet Biosciences has a consensus target price of $25.57, suggesting a potential upside of 293.41%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sagimet Biosciences 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64

Is INCR or SGMT more profitable?

InterCure's return on equity of 0.00% beat Sagimet Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A Sagimet Biosciences N/A -37.57% -35.52%

InterCure (INCR) Competitors

$0.85 -0.10 (-10.38%)

Closing price 03:59 PM Eastern

Extended Trading

$0.86 +0.01 (+1.40%)

As of 06:18 PM Eastern

Compare

INCR vs. IKT, LENZ, CNTX, NERV, and SGMT

Should you buy InterCure stock or one of its competitors? MarketBeat compares InterCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with InterCure include Inhibikase Therapeutics (IKT), LENZ Therapeutics (LENZ), Context Therapeutics (CNTX), Minerva Neurosciences (NERV), and Sagimet Biosciences (SGMT). These companies are all part of the "pharmaceutical products" industry.

How does InterCure compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and InterCure (NASDAQ:INCR) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

InterCure's return on equity of 0.00% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
InterCure	N/A	N/A	N/A

InterCure has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	842.96	-$48.26M	-$0.43	N/A
InterCure	$78.47M	0.59	-$10.37M	$0.03	28.34

3.8% of Inhibikase Therapeutics shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 7.3% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Inhibikase Therapeutics currently has a consensus price target of $5.40, suggesting a potential upside of 225.30%. Given Inhibikase Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Inhibikase Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	4 Strong Buy rating(s)	3.11
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than InterCure. MarketBeat recorded 2 mentions for Inhibikase Therapeutics and 1 mentions for InterCure. InterCure's average media sentiment score of 1.87 beat Inhibikase Therapeutics' score of 0.72 indicating that InterCure is being referred to more favorably in the news media.

Company	Overall Sentiment
Inhibikase Therapeutics	Positive
InterCure	Very Positive

Inhibikase Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, InterCure has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market.

Summary

InterCure beats Inhibikase Therapeutics on 9 of the 16 factors compared between the two stocks.

How does InterCure compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and InterCure (NASDAQ:INCR) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

InterCure has higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	10.81	-$82.13M	-$3.60	N/A
InterCure	$78.47M	0.59	-$10.37M	$0.03	28.34

InterCure has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. InterCure's return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-519.30%	-46.82%	-43.32%
InterCure	N/A	N/A	N/A

In the previous week, LENZ Therapeutics had 5 more articles in the media than InterCure. MarketBeat recorded 6 mentions for LENZ Therapeutics and 1 mentions for InterCure. InterCure's average media sentiment score of 1.87 beat LENZ Therapeutics' score of 0.90 indicating that InterCure is being referred to more favorably in the news media.

Company	Overall Sentiment
LENZ Therapeutics	Positive
InterCure	Very Positive

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 8.3% of InterCure shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

LENZ Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, InterCure has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market.

LENZ Therapeutics currently has a consensus target price of $29.80, indicating a potential upside of 352.89%. Given LENZ Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe LENZ Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

InterCure beats LENZ Therapeutics on 9 of the 16 factors compared between the two stocks.

How does InterCure compare to Context Therapeutics?

InterCure (NASDAQ:INCR) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Context Therapeutics has a consensus price target of $6.60, indicating a potential upside of 355.17%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

8.3% of InterCure shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

InterCure has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.61, meaning that its stock price is 61% more volatile than the broader market.

InterCure's return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Context Therapeutics	N/A	-59.95%	-54.78%

InterCure has higher revenue and earnings than Context Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.59	-$10.37M	$0.03	28.34
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A

In the previous week, Context Therapeutics had 2 more articles in the media than InterCure. MarketBeat recorded 3 mentions for Context Therapeutics and 1 mentions for InterCure. InterCure's average media sentiment score of 1.87 beat Context Therapeutics' score of 0.47 indicating that InterCure is being referred to more favorably in the media.

Company	Overall Sentiment
InterCure	Very Positive
Context Therapeutics	Neutral

Summary

Context Therapeutics beats InterCure on 8 of the 15 factors compared between the two stocks.

How does InterCure compare to Minerva Neurosciences?

InterCure (NASDAQ:INCR) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Minerva Neurosciences	N/A	N/A	-32.63%

In the previous week, InterCure and InterCure both had 1 articles in the media. InterCure's average media sentiment score of 1.87 equaled Minerva Neurosciences'average media sentiment score.

Company	Overall Sentiment
InterCure	Very Positive
Minerva Neurosciences	Very Positive

8.3% of InterCure shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

InterCure has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.59	-$10.37M	$0.03	28.34
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Minerva Neurosciences has a consensus target price of $10.50, indicating a potential upside of 124.84%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InterCure has a beta of 1.38, meaning that its share price is 38% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market.

Summary

InterCure beats Minerva Neurosciences on 6 of the 11 factors compared between the two stocks.

How does InterCure compare to Sagimet Biosciences?

InterCure (NASDAQ:INCR) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

8.3% of InterCure shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 14.7% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

InterCure's return on equity of 0.00% beat Sagimet Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
Sagimet Biosciences	N/A	-37.57%	-35.52%

InterCure has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Sagimet Biosciences has a beta of 3.41, indicating that its share price is 241% more volatile than the broader market.

In the previous week, InterCure and InterCure both had 1 articles in the media. InterCure's average media sentiment score of 1.87 beat Sagimet Biosciences' score of 0.80 indicating that InterCure is being referred to more favorably in the media.

Company	Overall Sentiment
InterCure	Very Positive
Sagimet Biosciences	Positive

Sagimet Biosciences has a consensus target price of $25.57, suggesting a potential upside of 293.41%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Sagimet Biosciences is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sagimet Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

InterCure has higher revenue and earnings than Sagimet Biosciences. Sagimet Biosciences is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.59	-$10.37M	$0.03	28.34
Sagimet Biosciences	$2M	105.89	-$51.04M	-$1.34	N/A

Summary

InterCure and Sagimet Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get InterCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INCR vs. The Competition

Export

Metric	InterCure	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$46.48M	$8.16B	$6.41B	$11.71B
Dividend Yield	N/A	2.51%	2.67%	5.55%
P/E Ratio	28.34	16.10	24.46	23.62
Price / Sales	0.59	6.75	500.50	105.26
Price / Cash	N/A	17.15	42.36	56.09
Price / Book	0.40	3.54	10.43	6.70
Net Income	-$10.37M	$225.32M	$3.56B	$337.26M
7 Day Performance	-18.26%	-0.12%	-1.39%	-1.41%
1 Month Performance	1.35%	1.43%	0.86%	1.15%
1 Year Performance	-42.75%	-4.31%	19.42%	22.61%

InterCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INCR InterCure	1.3657 of 5 stars	$0.85 -10.4%	N/A	-36.8%	$46.48M	$78.47M	28.34	350	Positive News Gap Down
IKT Inhibikase Therapeutics	2.2987 of 5 stars	$1.67 -1.8%	$5.50 +229.3%	N/A	$224.46M	$260K	N/A	6	Analyst Forecast
LENZ LENZ Therapeutics	3.7883 of 5 stars	$7.01 -1.7%	$29.80 +325.1%	-78.3%	$223.56M	$19.09M	N/A	110
CNTX Context Therapeutics	3.0116 of 5 stars	$2.06 -15.1%	$6.60 +221.2%	+116.2%	$222.35M	N/A	N/A	7	News Coverage
NERV Minerva Neurosciences	3.1438 of 5 stars	$4.68 -1.5%	$10.50 +124.4%	+157.6%	$221.30M	N/A	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INCR) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

InterCure (INCR) Competitors

INCR vs. IKT, LENZ, CNTX, NERV, and SGMT

How does InterCure compare to Inhibikase Therapeutics?

Summary

How does InterCure compare to LENZ Therapeutics?

Summary

How does InterCure compare to Context Therapeutics?

Summary

How does InterCure compare to Minerva Neurosciences?

Summary

How does InterCure compare to Sagimet Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

InterCure (INCR) Competitors

INCR vs. IKT, LENZ, CNTX, NERV, and SGMT

How does InterCure compare to Inhibikase Therapeutics?

Is IKT or INCR more profitable?

Which has preferable valuation and earnings, IKT or INCR?

Do institutionals & insiders hold more shares of IKT or INCR?

Do analysts recommend IKT or INCR?

Does the media favor IKT or INCR?

Which has more risk and volatility, IKT or INCR?

Summary

How does InterCure compare to LENZ Therapeutics?

Which has higher earnings & valuation, LENZ or INCR?

Is LENZ or INCR more profitable?

Does the media favor LENZ or INCR?

Do institutionals & insiders believe in LENZ or INCR?

Which has more volatility & risk, LENZ or INCR?

Do analysts prefer LENZ or INCR?

Summary

How does InterCure compare to Context Therapeutics?

Do analysts rate INCR or CNTX?

Do institutionals and insiders hold more shares of INCR or CNTX?

Which has more volatility & risk, INCR or CNTX?

Is INCR or CNTX more profitable?

Which has better earnings and valuation, INCR or CNTX?

Does the media prefer INCR or CNTX?

Summary

How does InterCure compare to Minerva Neurosciences?

Is INCR or NERV more profitable?

Does the media refer more to INCR or NERV?

Do insiders and institutionals believe in INCR or NERV?

Which has stronger valuation and earnings, INCR or NERV?

Do analysts rate INCR or NERV?

Which has more volatility and risk, INCR or NERV?

Summary

How does InterCure compare to Sagimet Biosciences?

Do insiders and institutionals have more ownership in INCR or SGMT?

Is INCR or SGMT more profitable?

Which has more volatility & risk, INCR or SGMT?

Does the media favor INCR or SGMT?

Do analysts prefer INCR or SGMT?

Which has higher valuation & earnings, INCR or SGMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INCR vs. The Competition

InterCure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools